ATE326231T1 - Mutierendes enterotoxin als nichttoxisches orales adjuvans - Google Patents

Mutierendes enterotoxin als nichttoxisches orales adjuvans

Info

Publication number
ATE326231T1
ATE326231T1 AT95928662T AT95928662T ATE326231T1 AT E326231 T1 ATE326231 T1 AT E326231T1 AT 95928662 T AT95928662 T AT 95928662T AT 95928662 T AT95928662 T AT 95928662T AT E326231 T1 ATE326231 T1 AT E326231T1
Authority
AT
Austria
Prior art keywords
enterotoxin
mutating
oral adjuvant
toxic oral
antigen
Prior art date
Application number
AT95928662T
Other languages
English (en)
Inventor
John D Clements
Bonny L Dickinson
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE326231T1 publication Critical patent/ATE326231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95928662T 1994-08-26 1995-07-18 Mutierendes enterotoxin als nichttoxisches orales adjuvans ATE326231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,848 US6019982A (en) 1994-08-26 1994-08-26 Mutant enterotoxin effective as a non-toxic oral adjuvant

Publications (1)

Publication Number Publication Date
ATE326231T1 true ATE326231T1 (de) 2006-06-15

Family

ID=23143827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928662T ATE326231T1 (de) 1994-08-26 1995-07-18 Mutierendes enterotoxin als nichttoxisches orales adjuvans

Country Status (22)

Country Link
US (2) US6019982A (de)
EP (1) EP0777490B1 (de)
JP (1) JP3860208B2 (de)
KR (1) KR100399258B1 (de)
CN (1) CN1182868C (de)
AT (1) ATE326231T1 (de)
AU (1) AU709779B2 (de)
BR (1) BR9508633A (de)
CA (1) CA2198586C (de)
CZ (1) CZ298131B6 (de)
DE (1) DE69534992T2 (de)
DK (1) DK0777490T3 (de)
ES (1) ES2265148T3 (de)
FI (1) FI120137B (de)
HU (1) HU222985B1 (de)
NO (1) NO317942B1 (de)
NZ (1) NZ291262A (de)
PL (1) PL182667B1 (de)
PT (1) PT777490E (de)
RU (1) RU2160606C2 (de)
WO (1) WO1996006627A1 (de)
ZA (1) ZA956412B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
AU3630093A (en) * 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
DK0725653T3 (da) 1993-10-05 2004-10-11 Celltech Pharmaceuticals Ltd Vaccinepræparater
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
JPH10502365A (ja) * 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
EP0909323B1 (de) * 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bakterioferritin aus helicobacter pylori
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
WO1999047165A1 (en) * 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Production of purified mutant enterotoxin for use as an adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
JP4551001B2 (ja) * 1999-03-03 2010-09-22 学校法人北里研究所 脂肪酸を構成成分とするワクチン製剤
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9919468D0 (en) 1999-08-17 1999-10-20 Smithkline Beecham Biolog Vaccine
AU5762299A (en) * 1999-09-15 2001-04-17 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1221970B1 (de) * 1999-10-18 2014-02-19 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und verfahren zur stimulierung einer immunantwort gegen infektiöse krankheitserreger
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
ATE357461T1 (de) 2000-08-25 2007-04-15 Aventis Pasteur Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
EP1316314A4 (de) * 2000-08-31 2004-12-29 Kitasato Inst VAKZINZUBEREITUNG MIT FETTSäURE
EP1372708B1 (de) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
EP1377299A4 (de) 2001-03-19 2009-11-11 Intercell Usa Inc Transkutane immunstimulation
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2003018054A1 (en) * 2001-08-31 2003-03-06 Chiron Srl. Helicobacter pylori vaccination
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040146533A1 (en) * 2002-08-27 2004-07-29 Miller Timothy J. Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
EP1581256A4 (de) * 2002-11-14 2006-06-07 Pfizer Prod Inc Verwendung von rmlt als marker-antigen für vakzine und als synergistisches adjuvans mit amphigen
US20060069052A1 (en) * 2003-02-14 2006-03-30 David Hone DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
WO2004073603A2 (en) * 2003-02-14 2004-09-02 Aeras Global Tuberculosis Vaccine Foundation Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
MXPA06002459A (es) 2003-09-02 2006-06-20 Glaxosmithkline Biolog Sa Vacuna.
RU2250780C9 (ru) * 2003-11-17 2005-12-10 ГНУ Научно-исследовательский институт пушного звероводства и кролиководства им. В.А. Афанасьева Штамм бактерий escherichia coli № рпмб, предназначенный для защиты пушных зверей от токсикозов, вызванных энтеротоксинами кишечных бактерий
EP1708744A4 (de) * 2003-12-09 2009-07-15 Intercell Usa Inc Gm1-bindungsdefiziente exotoxine zur verwendung als immunadjuvantien
RU2305558C2 (ru) * 2004-12-09 2007-09-10 Михаил Петрович Костинов Способ лечения хронических заболеваний лор-органов вирусной, бактериальной и смешанной вирусно-бактериальной этиологии у вич-инфицированных детей и подростков
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
CA2621666A1 (en) * 2005-09-09 2007-03-15 Universitaet Zuerich Antigens for vaccination against and detection of mycoplasma suis
WO2007091911A1 (fr) * 2006-02-09 2007-08-16 Institut Problem Pererabotki Uglevodorodov Sibirskogo Otdeleniya Rossiiskoi Akademii Nauk Sorbant, procédé de fabrication et procédé de séchage d'hydrocarbures
EP2514824A3 (de) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
CN101688194B (zh) 2007-05-23 2013-09-11 Uab研究基金会 去毒的肺炎球菌神经氨酸酶及其用途
RU2441879C2 (ru) * 2007-07-18 2012-02-10 Девелопмент Сентер Фор Байотекнолоджи МУТАНТНЫЙ ТЕРМОЛАБИЛЬНЫЙ ЭНТЕРОТОКСИН E.coli
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
ES2528648T3 (es) 2007-09-11 2015-02-11 University Of Guelph Inmunógenos polisacáridos de la Clostridium Difficile
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
BRPI0910168A2 (pt) * 2008-07-01 2019-09-24 Univ George Washington "vacina anti-helmíntica multivalente e método de vacinar um indivíduo em necessidade da mesma contra infecção por ancilóstomo e esquistossomose"
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
EP2668201A2 (de) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunologische zusammensetzungen mit hiv-gp41-polypeptidderivaten
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2015192216A1 (en) 2014-06-20 2015-12-23 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
EP3294448A4 (de) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Schnellverfahren zur extraktion von nukleinsäuren aus biologischen proben
EP3359651A1 (de) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN110075290A (zh) * 2018-01-25 2019-08-02 吴夙钦 流感黏膜疫苗组合物及其制备方法与应用
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
EP4699617A1 (de) 2024-08-22 2026-02-25 Scandinavian Biopharma Holding AB Oraler impfstoff gegen multiple diarrhöe-verursachende krankheitserreger

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
SU1678373A1 (ru) * 1989-10-18 1991-09-23 Киевский Научно-Исследовательский Институт Эпидемиологии И Инфекционных Болезней Им.Л.В.Громашевского Способ иммунокоррекции при зат жных формах гепатита
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007037301A1 (de) * 2007-08-07 2009-02-12 BSH Bosch und Siemens Hausgeräte GmbH Hausgeräteanordnung

Also Published As

Publication number Publication date
CZ56297A3 (en) 1997-10-15
ZA956412B (en) 1996-03-11
US6440423B1 (en) 2002-08-27
ES2265148T3 (es) 2007-02-01
US6019982A (en) 2000-02-01
EP0777490B1 (de) 2006-05-17
AU709779B2 (en) 1999-09-09
PT777490E (pt) 2006-10-31
CN1182868C (zh) 2005-01-05
NO970993L (no) 1997-04-25
EP0777490A1 (de) 1997-06-11
CN1164191A (zh) 1997-11-05
AU3233795A (en) 1996-03-22
EP0777490A4 (de) 1998-11-18
FI970799L (fi) 1997-04-24
RU2160606C2 (ru) 2000-12-20
CZ298131B6 (cs) 2007-07-04
JPH10505059A (ja) 1998-05-19
KR970705403A (ko) 1997-10-09
NZ291262A (en) 1999-02-25
HU222985B1 (hu) 2004-01-28
PL182667B1 (pl) 2002-02-28
NO317942B1 (no) 2005-01-10
FI120137B (fi) 2009-07-15
CA2198586C (en) 2010-10-12
NO970993D0 (no) 1997-03-04
BR9508633A (pt) 1997-09-30
PL318930A1 (en) 1997-07-21
FI970799A0 (fi) 1997-02-26
DE69534992T2 (de) 2007-05-10
CA2198586A1 (en) 1996-03-07
WO1996006627A1 (en) 1996-03-07
DE69534992D1 (de) 2006-06-22
DK0777490T3 (da) 2006-09-18
MX9701445A (es) 1998-05-31
JP3860208B2 (ja) 2006-12-20
HUT77869A (hu) 1998-09-28
KR100399258B1 (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DE69421939D1 (de) Nichttoxisches schleimhautadjuvans
EP0528859A4 (en) Oral vaccine comprising antigen surface-associated with red blood cells
AU1046792A (en) Pneumococcal polysaccharide conjugate vaccine
DE69331901D1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DK0725653T3 (da) Vaccinepræparater
ATE62270T1 (de) Herstellung des e.coli-lt-benterotoxinunterteils.
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
EA200300557A1 (ru) Комбинированные композиции адъювантов
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
RU96116250A (ru) Штамм pestivirus, используемый для изготовления лапинизированной вирус вакцины против классической чумы свиней
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
Vetkova et al. Protective effect of Pseudomonas aeruginosa polyvalent corpuscular vaccine in P. aeruginosa generalized chronic infection of mice with cyclophosphamide-induced leukopenia.
RU94042882A (ru) Препарат с иммуностимулирующей активностью
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0777490

Country of ref document: EP